Erica L. Mayer, MD, MPH

home / authors / erica-l-mayer-md-mph

Articles

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

Pooja Advani, MBBS, MD;Sofia Braga;Adam M. Brufsky, MD, PhD;Karthik V. Giridhar;Erica L. Mayer, MD, MPH;Kelly E. McCann;Ruth M. O’Regan;Cristina Saura;Seth A. Wander;Georg F. Bischof;Beth H. Lowenthal;Judith D. Bebchuk;Lisa D. Eli;Brian G. Barnett;Joyce A. O’Shaughnessy;Tufia C. Haddad
April 11th 2025
24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

Erica L. Mayer, MD, MPH;Mary Lou Smith;Annie Guérin;Dominick Latrémouille-Viau;Nisha C. Hazra;Yan Meng;Wendi Qu;Remi Bellefleur;Vaidyanathan Ganapathy;Liz Santarsiero;Robert Morlock;Maryam Lustberg
August 2nd 2024
7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

Adam M. Brufsky, MD, PhD;Hannah M. Linden, MD;Hope S. Rugo, MD;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Erica L. Mayer, MD, MPH
April 18th 2022
Erica L. Mayer, MD, MPH, Discusses New Targeted Therapies in Breast Cancer Treatment

Erica L. Mayer, MD, MPH, Discusses New Targeted Therapies in Breast Cancer Treatment

Erica L. Mayer, MD, MPH
December 23rd 2019

The expert explained her research focused on the role of CDK4/6 inhibitors in treating breast cancer.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Photosensitive Facial Rash Depicted Along with Polyarticular Arthralgias
Published: April 30th 2011 | Updated: July 26th 2025
Photosensitive Facial Rash Depicted Along with Polyarticular Arthralgias